Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Accured Expenses (2016 - 2025)

Dexcom (DXCM) has disclosed Change in Accured Expenses for 16 consecutive years, with -$10.1 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 103.66% to -$10.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $347.0 million through Dec 2025, up 63.91% year-over-year, with the annual reading at $347.0 million for FY2025, 63.91% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$10.1 million at Dexcom, down from -$2.3 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $449.9 million in Q4 2023, with the low at -$260.4 million in Q3 2023.
  • Average Change in Accured Expenses over 5 years is $52.2 million, with a median of -$1.4 million recorded in 2025.
  • The sharpest move saw Change in Accured Expenses crashed 722.64% in 2021, then surged 6445.45% in 2025.
  • Over 5 years, Change in Accured Expenses stood at -$118.5 million in 2021, then tumbled by 37.38% to -$162.8 million in 2022, then soared by 376.35% to $449.9 million in 2023, then crashed by 38.65% to $276.0 million in 2024, then plummeted by 103.66% to -$10.1 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$10.1 million, -$2.3 million, and $360.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.